Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
After First Use 28 Days Discard 28 days after first access
People with slow metabolism or liver and kidney problems may take longer to get rid of opioids
Preclinical research has demonstrated protective and healing effects on gastric mucosa, intestinal tissue, and esophageal damage
14.2 Monotherapy Use of MOUNJARO in Adult Patients with Type 2 Diabetes Mellitus SURPASS-1 (NCT03954834) was a 40-week double-blind trial that randomized 478 adult patients with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg, or placebo once weekly
The intensive protocol (advanced users) For users with established tolerance, specific therapeutic goals requiring more aggressive treatment, or those addressing significant tissue damage, higher doses may be appropriate
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
